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Abstract. – OBJECTIVE: Obstructive sleep
apnea syndrome (OSAS) is associated with ele-
vated cardiovascular morbidity and mortality.
Considering that oxidative stress is involved in
endothelial dysfunction and atherosclerosis de-
velopment, our aim was to examine lipid peroxi-
dation and protein oxidation, two parameters of
oxidative status, in a group of subjects with
OSAS.
PATIENTS AND METHODS: We consecutively
enrolled 48 patients (36 men and 12 women;
mean age 49.7±14.6 yrs) with OSAS, subse-
quently subdivided according to the apnea/hy-
popnea index (AHI) value in two subgroups:
Low (L= 21 subjects with AHI<30) and High (H=
27 subjects with AHI>30). We examined lipid
peroxidation, expressed as TBARS, and protein
oxidation, measured as carbonyl groups in
plasma samples from fasting venous blood.
RESULTS: We observed that TBARS and car-
bonyl groups were significantly higher in sub-
jects with AHI > 30 in comparison with the L sub-
group and the whole group of OSAS subjects. In
addition, we found that these parameters were
positively correlated with neck and waist circum-
ference, with the AHI value and with the oxygen
desaturation index, and negatively correlated
with the mean oxygen saturation.
CONCLUSIONS: Lipid peroxidation and pro-
tein oxidation in OSAS patients are significant-
ly correlated with the severity of the disease.
Key Words:
Cardiovascular risk, Lipid peroxidation, OSAS, Protein
oxidation.
Introduction
Obstructive sleep apnea syndrome (OSAS) is
characterized by repeated partial or complete ob-
structions of upper airways, usually occurring at
the level of the oropharynx, during sleep with re-
sulting apnea or hypopnea, with consequent in-
termittent arterial oxygen desaturation and sleep
disruption1. The gold standard for the treatment
of OSAS is continuous positive airway pressure
(CPAP) therapy, with or without associated O2,
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for correction of the upper airway obstructive
episodes and of the hypoxemia during sleep2.
Intermittent hypoxemia can increase sympatet-
ic tone, oxidative stress, pro-inflammatory cy-
tokine production, platelet aggregation, and
metabolic dysregulation3773. A recent meta-analy-
sis shows that OSAS is significantly and inde-
pendently associated with an increased risk of
cardiovascular diseases, cerebrovascular events
and all-cause mortality and that the prevalence of
cardiovascular events is related to OSAS
severity4. Patients with severe untreated OSAS
have an higher occurrence of fatal and non fatal
cardiovascular events in comparison with simple
snorers or OSAS patients treated with cPAP5.
Some authors have demonstrated early athero-
sclerotic lesions in OSAS subjects, which can be
reduced by CPAP treatment; therefore, OSAS is
considered an independent risk factor for coro-
nary artery disease (CAD) and it also increases
CAD mortality6. In a large observational cohort
study78 OSAS patients had a 2-fold increased risk
of stroke and this association was independent
from other cardiovascular and cerebrovascular
risk factors, such as hypertension.
Several papers have demonstrated an altered
inflammatory3 and oxidative status8 in OSAS. As
it is known, reactive oxygen species (ROS) and
reactive nitrogen species (RNS) are involved in
several clinical conditions. The main ROS is the
superoxide anion (O2-), which physiologically is
rapidly neutralized by anti-oxidant enzymes,
while, if generated in excess, oxidizes nitric ox-
ide (NO) producing peroxinitrite and starting a
cascade of ROS generation that leads to oxida-
tion of carbohydrates, lipids and proteins. Lipid
peroxidation generates some relatively stable end
products, such as malonyldialdehyde (MDA), hy-
droxynonenal (HNE), oxononenal (ONE) and
isoprostanes, while the oxidation of proteins pro-
duces advanced oxidation protein products
(AOPPs)9. Carbonylation is another irreversible
ROS-induced protein modification: ROS may di-
rectly oxidize lysine, arginine, proline or threo-
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nine residues or may react with carbohydrates
and lipids generating reactive carbonyl species
(RCS), such as ketoamine, ketoaldehydes, MDA,
HNE and ONE, that subsequently interact with
proteins9.
Examining the oxidative/antioxidant status of
patients with OSAS, an increased lipid10-12 and
protein oxidation10,13 can be found, with a parallel
decreased nitric oxide metabolites8, and antioxi-
dant defenses10,11,14.
Celec et al10 have observed elevated levels of
thiobarbituric acid reacting substances (TBARS),
marker of lipid peroxidation, in OSAS subjects,
that decreased after only 1 month of cPAP thera-
py. TBARS are positively correlated with OSAS
severity12,16-18, expressed as apnea/hypopnea in-
dex (AHI) or oxygen desaturation index (ODI),
and negatively correlated with the mean oxygen
saturation16. However, recently Ntalapascha et
al19 found no difference in TBARS levels be-
tween OSAS and normal subjects. Similarly,
some authors17 have found higher plasma MDA
levels in subjects with OSAS, while others20,21
demonstrated no significant differences in MDA
levels between normal and OSAS subjects. In the
paper of Vatansever et al17, MDA concentrations
were higher in subjects with severe OSAS, but
not in those with mild OSAS, in comparison with
normal controls, and significantly correlated with
AHI values. MDA levels may be improved by
cPAP therapy, as demonstrated by Yagihara et
al22. Also the levels of plasmatic 8-isoprostane
are higher in subjects with OSAS without pul-
monary or cardiac diseases, than in normal con-
trols and they are reduced by cPAP therapy23.
Regarding protein oxidation, in OSAS patients
an increase in AOPPs levels has been found10,24,
but no correlation between AOPPs and AHI has
been demonstrated25. However, protein carbonyl
content is elevated in subjects with severe OSAS
and significantly correlated with AHI value17. In
sample of mucosal and muscle tissue from upper
airways of severe OSAS patients an increased
protein carbonylation was observed13. Advanced
glycation end products (AGEs) and fructosamine,
indicators of carbonyl stress, are increased in
OSAS subjects and their production can be influ-
enced by cPAP treatment10.
Considering all these data, our aim was to ex-
amine lipid peroxidation and protein oxidation in
a group of subjects with OSAS, subsequently sub-
divided according to the apnea/hypopnea index.
Patients and methods
We consecutively recruited 48 patients (36
men and 12 women; mean age 50.3±14.68 yrs)
with obstructive sleep apnea syndrome from
those with suspected OSAS referred to our cen-
ter. Clinical history and physical examination
were performed in all subjects and Epworth
Sleepiness Scale (ESS) was also given. OSAS
was diagnosed after a 1-night cardiorespiratory
sleep study: apneas were defined as the cessation
of airflow for ≥10 seconds and hypopneas were
defined as a transient reduction of breathing ≥
50% with an oxygen desaturation of ≥3% or as a
reduction of breathing ≥ 30% with an oxygen de-
saturation of ≥ 4% for ≥10 seconds. Obstructive
apneas and hypopneas were distinguished from
central events by the detection of respiratory ef-
forts during the event. AHI was defined as the
number of obstructive apneas and hypopneas per
hour of sleep. Patients with an AHI ≥ 5 were con-
sidered as OSAS and then they were subdivided
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All OSAS patients Mild OSAS Severe OSAS F
Age (years) 49.7 ± 14.6 45.3 ± 14.4 52.8 ± 14.2 1.549
BMI (kg/m2) 35.37 ± 7.31 35.72 ± 8.49 35.10 ± 6.47 0.037
Waist circumference (cm) 118.8 ± 16.1 114.2 ± 14.5 122.5 ± 16.6 1.341
Neck circumference (cm) 44.41 ± 4.53 41.50 ± 3.25 46.62 ± 4.15* 6.80a
ESS 11.07 ± 5.12 9.18 ± 3.69 12.42 ± 5.62 2.07
AHI 38.47 ± 25.66 15.13 ± 8.15¶ 56.63 ± 18.90§** 22.7b
mSO2 (%) 91.1 ± 3.68 93.4 ± 2.68 89.5 ± 3.45* 6.82a
ODI 39.34 ± 29.03 14.28 ± 9.39§ 55.38 ± 25.75#** 12.8b
Table I. Mean ± S.D. of age, anthropometric characteristics and OSAS parameters in the whole group of OSAS patients and
in the two subgroups with respectively mild and severe disease
a p < 0.01 b p < 0.001 (ANOVA)
# p < 0.05 § p < 0.01 ¶ p < 0.001 vs all OSAS patients (Bonferroni)
* p < 0.01 ** p < 0.001 vs mild OSAS (Bonferroni)
according to the AHI value in two subgroups:
Low (L= 21 subjects with AHI<30) and High
(H= 27 subjects with AHI>30). Therefore, the
Low subgroup included patients with mild to
moderate OSAS, while the H subgroup included
the patients with severe OSAS. Means and S.D.
of age, BMI, waist circumference, neck circum-
ference, AHI, oxygen desaturation index (ODI),
mean nocturnal SO2 are reported in Table I. 23 of
the OSAS patients had arterial hypertension, 10
patients had diabetes mellitus and 6 had cardio-
vascular disease (history of myocardial infarction
or stroke). Each subject gave the informed con-
sent and the study was approved by the Ethical
Committee.
On fasting venous blood, collected by punc-
ture from the antecubital vein of each subject and
immediately transferred to glass tube anticoagu-
lated with EDTA-K3, we evaluated lipid peroxi-
dation and protein carbonyl (PC) groups.
Lipid peroxidation was evaluated in plasma by
detection of thiobarbituric acid-reactive sub-
stances (TBARS), generated by peroxidative
processes, which include lipid peroxides and
malonyldialdehyde. The evaluation of TBARS
was made by fluorimetry, using 1,1,3,3-tetram-
ethoxypropane as standard26.
The PC groups were measured by an enzyme-
linked immunosorbent assay (ELISA) kit (Bio-
Cell PC test kit, Enzo Life Sciences AG, Lausen,
Switzerland). It uses the classic PC reagent
2,4dinitrophenyl-hydrazyne (DNP), which reacts
with the PC forming a stable hydrazone product.
In brief, plasma samples were incubated with
DNP, and then plasma proteins were nonspecifi-
cally adsorbed to the wells of an ELISA plate.
Unconjugated DNP and non-protein constituents
were washed away. The absorbed proteins were
probed with a biotinylated anti-DNP antibody,
followed by streptavidin-linked horseradish per-
oxidase. A chromatin reagent was added, and the
reaction was stopped by adding an acid solution.
Absorbance for each well was measured at 450
nm and related to a standard curve prepared for
serum albumin, containing increasing propor-
tions of hypoclorous acid-oxidized protein, cali-
brated colorimetrically. Total protein concentra-
tion in plasma samples was evaluated by the
method of Lowry et al27.
Statistical Analysis
Data were expressed as means ± S.D. The sta-
tistical difference between the entire group of
OSAS patients, the L subgroup and the H sub-
group was estimated using the 1-way analysis of
variance (ANOVA) integrated with the Bonfer-
roni test. The correlations were performed em-
ploying the linear regression test. The null hy-
pothesis was rejected for p values < 0.05.
Results
Subdividing the entire group of OSAS accord-
ing to the AHI value, we observed that the lipid
peroxidation, expressed as TBARS, was signifi-
cantly increased in the H subgroup in compari-
son with the L subgroup and the entire group
(Table II). The same behavior was observed eval-
uating the protein oxidation, and in fact the car-
bonyl groups were significantly increased in the
H subgroup in comparison with the L subgroup
and the entire group of OSAS patients (Table II).
Regarding the demographic characteristics, in the
entire group of OSAS patients we found a posi-
tive correlation between TBARS and neck cir-
cumference (r = 0.88, p < 0.0002). About the
polysomnographic parameters we found a posi-
tive correlation between TBARS and AHI value
(r = 0.88, p < 0.0001), and between TBARS and
ODI (r = 0.88, p < 0.0001) and a negative corre-
lation between TBARS and mean oxygen satura-
tion (r = –0.52, p < 0.0003) (Figure 1). Regarding
the protein oxidation, we observed a positive cor-
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All OSAS patients Mild OSAS Severe OSAS F
TBARS (nmol/ml) 6.431 ± 1.635 5.247 ± 0.469§ 7.351 ± 1.629#* 12.2a
PCO (nmol/mg prot.) 0.316 ± 0.120 0.230 ± 0.088§ 0.382 ± 0.099#* 11.6a
Table II. Mean ± S.D. of oxygen status parameters in the whole group of OSAS patients and in the two subgroups with re-
spectively mild and severe disease.
a p < 0.001 (ANOVA)
# p < 0.05 § p < 0.01 vs all OSAS patients (Bonferroni’s test)
* p < 0.001 vs mild OSAS (Bonferroni’s test)
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relation not only between carbonyl groups and
neck circumference (r = 0.61, p < 0.0001), but al-
so between carbonyl groups and waist circumfer-
ence (r = 0.35, p < 0.02). We also observed a
positive correlation between carbonyl groups and
AHI values (r = 0.68, p < 0.0001), and between
carbonyl groups and ODI (r = 0.63, p < 0.0001)
and a negative correlation between carbonyl
groups and mean oxygen saturation (r = –0.46, p
< 0.001) (Figure 1).
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Figure 1. Correlations between oxidative stress parameters and polysomnographic parameters.
Discussion
The principal information that emerges from
this research is the behavior of lipid peroxidation
and protein oxidation, between them significant-
ly interrelated (r = 0.61, p < 0.0001), that results
influenced by the degree of severity of this syn-
drome. In these last decades, the particular atten-
tion addressed towards the oxidative status in
OSAS patients has been related especially to the
fact that its impairment, associated with the in-
crease in sympatethic tone, might be considered
one of the links between OSAS and the increase
in cardiovascular events.
Our data show clearly that lipid peroxidation
and protein oxidation discriminate subjects with
mild to moderate OSAS from those with severe
OSAS. Considering that the literature data under-
line how the cardiovascular morbidity and mor-
tality4,5,7,28, especially in OSAS patients with pre-
vious cardiovascular diseases, are significantly
related to the degree of the OSAS severity, these
data deserve to be considered.
In this group of OSAS patients no correlation
was found among lipid peroxidation and protein
oxidation with age and body mass index and this
datum agrees with those of other authors16,17.
However, we observed a positive correlation of
these two parameters with neck and waist cir-
cumference. These findings partially agree with
those of Vatansever et al17 and contrast with those
of Papandreu16.
Another aspect of this research is the interrela-
tionship between these two parameters of the ox-
idative status and the polysomnographic charac-
teristics. In agreement with others12,16-18, we
found a positive correlation between TBARS and
AHI values and between TBARS and ODI, and a
negative correlation between TBARS and mean
oxygen saturation. In contrast with Mancuso et
al25, but in agreement with Vatansever et al17, we
observed a significant correlation between pro-
tein oxidation and AHI values. We also found a
positive correlation between carbonyl groups and
ODI, and a negative correlation between car-
bonyl groups and mean oxygen saturation.
The impairment of the oxidative status, and in
particular of the lipid peroxidation and protein
oxidation, is dependent on the hypoxia-reoxy-
genation episodes that characterize OSAS3,29. An
increased mitochondrial ROS production in cul-
tured endothelial cells exposed to hypoxia has
been demonstrated29. In vitro hypoxia induces al-
so the activation of leukocytes and the production
of ROS and Lavie et al29 have demonstrated an
increased ROS generation by monocytes and
neutrophils from OSAS patients activated by
phorbol myristate acetate. In addition, ROS are
involved in signaling pathways activation, as they
influence the activity of mitogen-activated pro-
tein kinase (MAPK), able to induce several nu-
clear transcription factors29. In particular, NF-kB
starts a cascade of inflammatory pathways lead-
ing to the production of cytokines and adhesion
molecules implicated in atherosclerosis develop-
ment, while the hypoxya-inducible factor 1α
(HIF-1α) increases the sympathetic nerve activi-
ty [3,29]. Jelic et al30 observed an increased NF-
κB activation in freshly venous endothelial cells
from obese OSAS in comparison with obeses
without OSAS, which was associated with en-
dothelial dysfunction demonstrated by reduced
levels of activated eNOS.
Conclusions
Lipid peroxidation and protein oxidation are
dependent on the degree of severity of OSAS pa-
tients. In the next future we may observe if the
treatment of OSAS using cPAP will came out
able to modify at the same time and proportional-
ly these two oxidative status parameters.
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